Rapport Therapeutics (NASDAQ:RAPP - Get Free Report)'s stock price gapped down before the market opened on Monday . The stock had previously closed at $14.81, but opened at $14.06. Rapport Therapeutics shares last traded at $13.88, with a volume of 7,822 shares.
Rapport Therapeutics Stock Performance
The stock's 50-day simple moving average is $20.66.
Institutional Investors Weigh In On Rapport Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in RAPP. Values First Advisors Inc. acquired a new position in shares of Rapport Therapeutics in the 3rd quarter valued at $31,000. BNP Paribas Financial Markets purchased a new stake in shares of Rapport Therapeutics in the third quarter valued at about $34,000. The Manufacturers Life Insurance Company boosted its stake in shares of Rapport Therapeutics by 2.4% during the third quarter. The Manufacturers Life Insurance Company now owns 77,344 shares of the company's stock worth $1,584,000 after buying an additional 1,828 shares during the period. Barclays PLC grew its holdings in shares of Rapport Therapeutics by 36.8% during the third quarter. Barclays PLC now owns 12,863 shares of the company's stock worth $264,000 after buying an additional 3,463 shares during the last quarter. Finally, JPMorgan Chase & Co. acquired a new position in Rapport Therapeutics in the 3rd quarter valued at about $83,000.
Rapport Therapeutics Company Profile
(
Get Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Featured Stories
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
